ERCC1 and XRCC1 Gene Polymorphisms Predict Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer

Warnecke-Eberz, Ute; Vallböhmer, Daniel; Alakus, Hakan; Kütting, Fabian; Lurje, Georg; Bollschweiler, Elfriede; Wienand-Dorweiler, Anke; Drebber, Uta; Hölscher, Arnulf H.; Metzger, Ralf

doi:10.1007/s11605-009-0881-z

Cited by 61 publications

(41 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results suggest that T19007C SNP in the ERCC1 gene does not influence OS in our patients, in contrast to others, which found an association with response to platinum-based chemotherapy and survival in esophageal cancer, colorectal cancer, ovarian cancer and non-small cell lung cancer patients (17,(34)(35)(36). A proposed mechanism is that T19007C SNP may decrease ERCC1 mRNA stability and consequently, protein expression.…”

Section: Discussioncontrasting

confidence: 95%

ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

Castro

Pasini²,

Siqueira³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Adjuvant cisplatin-based chemoradiation improves survival in HNSCC patients presenting with risk features. ERCC1 (excision repair cross-complementation group 1) is associated with resistance to chemo-and radiation therapy and may have a prognostic value in HNSCC patients. Here we studied ERCC1 expression and the polymorphism T19007C as prognostic markers in these patients. This is a retrospective and translational analysis, where ERCC1 protein expression was evaluated by immunohistochemistry, using an H-score, and mRNA expression was determined by RT-PCR. T19007C genotypes were detected by PCR-RFLP carried out using DNA template extracted from normal lymph nodes. A high H-score was seen in 32 patients (54%), who presented better 5-year overall survival (5-y OS: 50% vs. 18%, HR 0.43, p=0.026). Fifteen out of 45 patients (33%), with high mRNA expression, presented better 5-year overall survival (OS) (86% vs. 30%, HR 0.26, p=0.052). No OS difference was detected among T19007C genotypes. High H-score and mRNA expression remained significant as favorable prognostic factors in a multivariate analysis. Collectively, our results suggest that high ERCC1 expression seems to be associated with better OS rates in HNSCC patients submitted to adjuvant cisplatin-based chemoradiation.

show abstract

Section: Discussioncontrasting

confidence: 95%

ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

Castro

Pasini²,

Siqueira³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…XRCC1 gene polymorphisms are reported to be correlated with the treatment outcome of cisplatin-based chemotherapy in several kinds of cancers, such as gastric cancer, colorectal cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, and esophageal cancer (Warnecke-Eberz et al, 2009;Giovannetti et al, 2011;Miao et al, 2012;Chen et al, 2013;Cao et al, 2014;Wu et al, 2014). Currently, several studies have reported the association between XRCC1 genetic polymorphisms and treatment outcome of advanced NSCLC (Yuan et al, 2006;Wang et al, 2004Wang et al, , 2008Sun et al, 2009;Li et al, 2011;Ke et al, 2012;Han et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer

Mao

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Glutathione S-transferase P1 (GSTP1) and X-ray repair cross-complementing group 1 (XRCC1) genetic variations may influence the efficacy of chemotherapy in various cancers. We investigated the possible roles of GSTP1 Ile105Val and XRCC1 Arg194Trp, and Arg399Gln gene polymorphisms in the prognosis of advanced non-small cell lung carcinoma (NSCLC) patients with cisplatin-based chemotherapy. Between January 2010 and December 2012, this study consecutively recruited 141 patients with advanced NSCLC from the First People's Hospital of Yunnan Province. Logistic regression analysis showed that individuals carrying the GG genotype were associated with a better response to chemotherapy than those with the wide-type genotype, with an adjusted odds ratio (95% confidence interval, CI) of 4.07 (1.06-25.06). Moreover, we observed that the AA genotype of XRCC1 Arg399Gln was correlated with a greater complete response + partial response to chemotherapy than that with the GG genotype (odds ratio = 2.71, 95%CI = 1.13-10.08). Based on the Cox hazard proportional model, the GG genotype of GSTP1 Ile105Val was found to be associated with a lower risk of death from all causes as compared to that with the AA genotype (hazard ratio = 0.07, 95%CI = 0.01-0.34). In summary, we suggest that GSTP1 Ile105Val and XRCC1 Arg399Gln polymorphisms could influence the response to chemotherapy and survival of advanced NSCLC.

show abstract

“…As a result of these studies, ERCC1 overexpression was suggested as an indicator of resistance against platin-based chemotherapies. Some cancers exhibit ERCC1 overexpression, as was shown with immunohistochemistry or RT-PCR [1,2].…”

Section: Introductionmentioning

confidence: 67%

ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer

Bilen

Tekin

Topdağı

2014

EAJM

View full text Add to dashboard Cite

Objective: "Excision Repair Cross-Complementation Group 1" (ERCC1) enzyme is a vitally important basic protein required for DNA repair. Recent studies suggest that ERCC1 is involved in resistance to antracycline-based chemotherapy regimens. In this study, we aimed to analyze ERCC1 expression in lung and esophageal cancer patients. We also aimed to investigate the possible correlation between the ERCC1 expression levels and patient demographic information. Materials and Methods:Twenty esophageal and 20 non-small cell lung cancer (NSCLC) patients diagnosed between December 2009 and December 2010, via either endoscopic, bronchoscopic or tru-cut biopsy, were included in this study. The ERCC1 expression levels were analyzed by the reverse transcriptase-polymerase chain reaction (RT-PCR) method in RNA samples extracted from pathological biopsy specimens. The patient demographic information was also recorded. Results:There was no significant correlation between the ERCC1 expression level and demographic parameters, including the tumor, node, metastatis (TNM) staging, World Health Organization (WHO) grading, age, gender, hemoglobin level and albumin level, in the patient groups. The mean ERCC1 expression levels in the NSCLC and esophageal cancer patients were 0.71±0.85 and 0.62±0.78, respectively. The ERCC1 expression level was elevated in 15% of each patient group. Conclusion:Analysis of the ERCC1 expression in NSCLC and esophageal cancer patients prior to chemotherapy would be useful for personalized chemotherapy regimens and would provide more accurate prognostic information for the patient.Key Words: ERCC1 expression, lung cancer, esophageal cancer ÖzetAmaç: "Excision Repair Cross-Complementation Group 1"(ERCC1) enzimi DNA tamiri için gerekli temel proteinlerden bir tanesi olup hayati öneme sahiptir. Yapılan son çalışmalarda ERCC1'in antrasiklin bazlı kemoterapi rejimlerine karşı gelişen direnç ile ilişkili olabileceğini düşün-dürmektedir. Bu çalışmada, ERCC1 ekspresyonunu küçük hücre dışı akciğer kanseri ve özofagus kanseri hastalarında araştırmayı amaçladık. Aynı zamanda ERCC1 ekspresyonu ile hastaların demografik verileri arasında olabilecek muhtemel ilişkiyi araştırmayı amaçladık. Gereç ve Yöntem:Aralık 2009 ve Aralık 2010 tarihleri arasında, endoskopik, bronkoskopik veya tru-cut biyopsi ile özofagus kanseri tanısı almış 20 hasta ve küçük hücre dışı akciğer kanseri (KHDAK) tanısı almış 20 hasta çalışmaya dahil edildi. Hastalara ait demografik bilgiler kayıt edildi. Çalışma sonunda ERCC1 ekspresyonu, tanı koydurucu patoloji bloklarından elde edilen dokusal RNA örneklerinde RT-PCR (reverse transcriptase-polymerase chain reaction) metodu ile değerlendirildi. Bulgular:Hastaların ERCC1 ekspresyon düzeyi ile TNM evrelemesi, Dünya sağlık örgütü (WHO) derecesi, yaş, cinsiyet, hemoglobulin ve albumin serum düzeyi gibi parameterelerin herhangi birisi ile korrelasyonu tespit edilemedi. KHDAK hastalarında ve özofagus kanseri hastalarında ölçülen ortalama ERCC1 ekspresyonu düzeyi sırası ile 0,71±0,85 and 0,62±0,78 ol...

show abstract

ERCC1 and XRCC1 Gene Polymorphisms Predict Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer

Abstract: Our data support the role of ERCC1 as a predictive marker for therapy response. Single-nucleotide polymorphisms of ERCC1 and XRCC1 could be applied to further individualize treatment strategies.

Cited by 61 publications

References 49 publications

ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer

ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer

Contact Info

Product

Resources

About